Table 2 List of definitions and derived variables used in the study
Initial mHSPC treatment | The first treatment that a patient received in the mHSPC setting |
|---|---|
NHA drugs | abiraterone, enzalutamide, apalutamide, darolutamide |
Chemotherapy drugs | cabazitaxel, docetaxel, mitoxantrone, cisplatin, paclitaxel, carboplatin, etoposide, estramustine, ifosfamide |
ADT drugs | degarelix, goserelin, leuprorelin, triptorelin, histrelin, bicalutamide, flutamide, nilutamide, ketoconazole, chlormadinone, cyproterone, buserelin |
Immunotherapy drugs | sipuleucel-T, pembrolizumab |
Radiotherapy drugs | radium-223, strontium 89 |
Corticosteroid drugs | prednisone, prednisolone, methylprednisolone, hydrocortisone, dexamethasone, betamethasone |
Other drugs | diethylstilbestrol, padeliporfin, peplomycin sulfate, any other drug therapies not previously specified |
NHA (± ADT) | Patients who received NHA (± ADT) |
Chemotherapy (± ADT) | Patients who received chemotherapy (± ADT) |
ADT alone | Patients who received ADT alone |
Other combination including NHA | Patients who received any NHA drugs (not as a NHA (± ADT)) |
Chemotherapy combination | Patient who received a chemotherapy drug (not as a chemotherapy (± ADT)) in their initial mHSPC treatment. This does not include patients who received an NHA (± ADT) or NHA in combination |
Any other combination | Patients who received a treatment not captured in the NHA (± ADT), chemotherapy (± ADT), ADT alone, other combination including NHA or chemotherapy combination treatment groups |
Any NHA | Patients who received a NHA drug as either (± ADT) or in combination (± ADT) |
No NHA | Patients who did not receive a NHA drug as either (± ADT) or in combination (± ADT) |
High-risk disease | Patients with two of the following: Gleason score of 8 + , presence of visceral metastases, or 3 + bone lesions |
Low-risk disease | Patients with ≤ 1 of the following: Gleason score of 8 + , presence of visceral metastases, or 3 + bone lesions |
High disease volume | Patients with either of the following: presence of visceral metastases, or 4 + bone lesions with ≥ 1 beyond the vertebral bodies/pelvis |
Low disease volume | Patients with neither of the following: presence of visceral metastases, nor 4 + bone lesions with ≥ 1 beyond the vertebral bodies/pelvis |